Ono Hiroyuki, Tanaka Ryota, Suzuki Yosuke, Oda Ayako, Ozaki Takashi, Tatsuta Ryosuke, Maeshima Keisuke, Ishii Koji, Ohno Keiko, Shibata Hirotaka, Itoh Hiroki
Department of Clinical Pharmacy, Oita University Hospital, Oita, Japan.
Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Tokyo, Japan.
Clin Pharmacol Ther. 2021 Oct;110(4):1096-1105. doi: 10.1002/cpt.2375. Epub 2021 Aug 10.
Organic anion transporting polypeptides (OATPs) 1B are drug transporters mainly expressed in the sinusoidal membrane. In previous reports, genetic factor, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), which is one of the uremic toxins, inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) decreased OATP1B1 activity in vitro, but in vivo effects of these factors have not been elucidated. Plasma coproporphyrin-I (CP-I) is spotlighted as a highly accurate endogenous substrate of OATP1B. This study focused on patients with rheumatoid arthritis (RA) and evaluated the influence of several factors comprising gene polymorphisms, uremic toxins, and inflammatory cytokines on OATP1B activity using plasma CP-I concentration. Thirty-seven outpatients with RA who satisfied the selection criteria were analyzed at the time of recruitment (baseline) and at the next visit. OATP1B115 carriers tended to have higher CP-I concentration compared with noncarriers. Plasma CP-I correlated positively with CMPF concentration, but did not correlate with IL-6 or TNF-α concentration. Multiple logistic regression analysis by stepwise selection identified plasma CMPF concentration and OATP1B115 allele as significant factors independently affecting plasma CP-I concentration at baseline and at the next visit, respectively. In conclusion, the present results suggest that inflammatory cytokines do not have clinically significant effects on OATP1B activity, whereas the effects of genetic polymorphisms and uremic toxins should be considered.
有机阴离子转运多肽(OATPs)1B是主要表达于肝血窦膜的药物转运体。在以往的报道中,作为尿毒症毒素之一的遗传因子3 - 羧基 - 4 - 甲基 - 5 - 丙基 - 2 - 呋喃丙酸(CMPF)以及肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)等炎性细胞因子在体外可降低OATP1B1的活性,但这些因素在体内的作用尚未阐明。血浆粪卟啉-I(CP-I)作为OATP1B高度准确的内源性底物受到关注。本研究聚焦于类风湿关节炎(RA)患者,利用血浆CP-I浓度评估基因多态性、尿毒症毒素和炎性细胞因子等多种因素对OATP1B活性的影响。对37例符合入选标准的RA门诊患者在入组时(基线)和下次就诊时进行分析。与非携带者相比,OATP1B115携带者的CP-I浓度往往更高。血浆CP-I与CMPF浓度呈正相关,但与IL-6或TNF-α浓度无关。通过逐步选择进行的多因素logistic回归分析确定,血浆CMPF浓度和OATP1B115等位基因分别是在基线和下次就诊时独立影响血浆CP-I浓度的显著因素。总之,目前的结果表明炎性细胞因子对OATP1B活性没有临床显著影响,而应考虑基因多态性和尿毒症毒素的影响。